Blood Screening Market by Technology (Nucleic Acid Amplification  (rPCR)  ELISA  (CLIA  Fluorescence assay)  Rapid Test  NGS  Western Blotting)  Product (Instrument  Reagent & Kits  Software) & End User (Blood Bank  Hospital) - Global Forecasts to 2021

Blood Screening Market by Technology (Nucleic Acid Amplification (rPCR) ELISA (CLIA Fluorescence assay) Rapid Test NGS Western Blotting) Product (Instrument Reagent & Kits Software) & End User (Blood Bank Hospital) - Global Forecasts to 2021

MarketsandMarkets | ID: 1541222301738 | Published at: 2016-12-21 | Pages: 153

  • €4.821,70


The blood screening market is expected to reach USD 2.80 billion by 2021 from USD 1.76 billion in 2016, at a CAGR of 9.7%. The global blood screening market is categorized based on technology, product & service, end user, and region. The technology segment includes nucleic acid tests (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS). The NAT segment is expected to grow at the highest CAGR during the forecast period. Major factors contributing to the growth in this segment are increasing number of blood donations, rising incidence of various infectious diseases, and increasing disposable income to pay for advanced blood screening procedures including NAT-test.
On the basis of product & service, the market is segmented into reagents & kits, instruments, and software & services. In 2016, the reagents and kits segment is expected to account for the largest share of the market. The repeated usage of reagents and kits is the key driving factor driving the growth of this segment.
On the basis of end user, the market is segmented into blood banks and hospitals. In 2016, the blood banks segment is expected to account for the largest of the market. This is primarily due to the increasing number of organ transplantation surgeries, increasing demand for donated blood, rising awareness regarding the safety of blood, and increasing number of donations worldwide.
Geographically, the blood screening market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The growth of this market can be attributed to the increasing adoption of nucleic acid tests (NAT) in this region. In addition, the increasing participation of various government associations in blood donations and screening & transfusion activities also supports the growth of the North American blood screening market.
Globally, the blood screening market is witnessing substantial growth due to factors such as increasing number of blood donations and blood donors, growing affordability and adoption of nucleic acid test (NAT) for blood screening, rising awareness regarding the safety of donated blood, growing demand for donated blood, and increasing prevalence/incidence of infectious diseases.
The major players in this market include Grifols (Spain), Siemens Healthineers (Germany), Roche Diagnostics (Switzerland), Ortho Clinical Diagnostics, Inc. (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), bioMérieux (France), Beckman Coulter, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Becton, Dickinson and Company (U.S.).
Research Coverage:
Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The abovementioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the blood screening market.

Reasons to Buy the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the blood screening market. The report analyses the blood screening market by technology, product & service, end user, and region
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the blood screening market
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the blood screening market
• Market Development: Comprehensive information about emerging markets. This report analyses the market for various blood screening products across geographies
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the blood screening market

TABLE OF CONTENTS

1 INTRODUCTION 14

  • 1.1 OBJECTIVES OF THE STUDY 14
  • 1.2 MARKET DEFINITION 15
  • 1.3 MARKET SCOPE 15
    • 1.3.1 MARKETS COVERED 15
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY 16
  • 1.4 CURRENCY 16
  • 1.5 LIMITATIONS 16
  • 1.6 STAKEHOLDERS 16
    2 RESEARCH METHODOLOGY 17
  • 2.1 SECONDARY DATA 18
    • 2.1.1 KEY DATA FROM SECONDARY SOURCES 18
  • 2.2 PRIMARY DATA 19
    • 2.2.1 KEY DATA FROM PRIMARY SOURCES 19
  • 2.3 MARKET SIZE ESTIMATION 20
    • 2.3.1 BOTTOM-UP APPROACH 20
    • 2.3.2 TOP-DOWN APPROACH 21
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION 22
  • 2.5 ASSUMPTIONS FOR THE STUDY 23
    3 EXECUTIVE SUMMARY 24
  • 3.1 INTRODUCTION 24
  • 3.2 CURRENT SCENARIO 25
  • 3.3 CONCLUSION 28
    4 PREMIUM INSIGHTS 29
  • 4.1 BLOOD SCREENING MARKET 29
  • 4.2 BLOOD SCREENING MARKET, BY REGION & TECHNOLOGY 30
    5 MARKET OVERVIEW 31
  • 5.1 INTRODUCTION 32
  • 5.2 MARKET DYNAMICS 32
    • 5.2.1 DRIVERS 33
      • 5.2.1.1 Increasing number of blood donations and blood donors 33
      • 5.2.1.2 Increasing demand of donated blood 33
      • 5.2.1.3 Rising prevalence of infectious diseases 34
      • 5.2.1.4 Growing affordability and adoption of NAT for blood screening 35
      • 5.2.1.5 Rising awareness regarding the safety of donated blood 35
    • 5.2.2 RESTRAINTS 36
      • 5.2.2.1 Capital expenditure and operating costs of NAT 36
      • 5.2.2.2 Lack of regulations mandating the use of NAT in developing countries 36
      • 5.2.2.3 Emergence of alternative technologies 36
    • 5.2.3 OPPORTUNITIES 36
      • 5.2.3.1 Pathogen reduction technology 36
      • 5.2.3.2 Multiplex tests 36
      • 5.2.3.3 Emerging economies 37
    • 5.2.4 CHALLENGES 37
      • 5.2.4.1 Price reduction 37
        6 BLOOD SCREENING MARKET, BY TECHNOLOGY 38
  • 6.1 INTRODUCTION 39
  • 6.2 BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS CONDUCTED) 40
  • 6.3 NUCLEIC ACID TEST (NAT) 41
    • 6.3.1 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) 42
    • 6.3.2 REAL-TIME POLYMERASE CHAIN REACTION (PCR) 43
  • 6.4 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 44
    • 6.4.1 ELISA MARKET, BY PLATFORM 45
      • 6.4.1.1 Chemiluminescence Immunoassay (CLIA) 46
      • 6.4.1.2 Fluorescence Immunoassay (FIA) 46
      • 6.4.1.3 Colorimetric Immunoassay (CI) 47
    • 6.4.2 ELISA MARKET, BY GENERATION 48
      • 6.4.2.1 First-generation ELISA 49
      • 6.4.2.2 Second-generation ELISA 50
      • 6.4.2.3 Third-generation ELISA 50
      • 6.4.2.4 Fourth-generation & Above 51
  • 6.5 RAPID TESTS 52
  • 6.6 WESTERN BLOT ASSAY 53
  • 6.7 NEXT-GENERATION SEQUENCING (NGS) 54
    7 BLOOD SCREENING MARKET, BY PRODUCT AND SERVICE 56
  • 7.1 INTRODUCTION 57
  • 7.2 REAGENTS & KITS 58
    • 7.2.1 NAT REAGENTS & KITS 59
      • 7.2.1.1 Enzymes and Polymerases 60
      • 7.2.1.2 Standards and Controls 60
      • 7.2.1.3 Probes and Primers 60
      • 7.2.1.4 Buffers, Nucleotides and Solutions 60
      • 7.2.1.5 Labeling and Detection Reagents 60
  • 7.2.2 ELISA REAGENTS & KITS 61
    • 7.2.2.1 Immunosorbents 62
    • 7.2.2.2 Controls 62
    • 7.2.2.3 Conjugates (Antigen or antibody-conjugated enzyme) 62
    • 7.2.2.4 Substrates (of enzymes) 62
    • 7.2.2.5 Sample diluents and wash solutions 63
  • 7.2.3 OTHER REAGENTS 63
  • 7.3 INSTRUMENTS 64
    • 7.3.1 RENTAL PURCHASE 65
    • 7.3.2 OUTRIGHT PURCHASE 66
  • 7.4 SOFTWARE AND SERVICES 66
    8 BLOOD SCREENING MARKET, BY END USER 68
  • 8.1 INTRODUCTION 69
  • 8.2 BLOOD BANKS 70
  • 8.3 HOSPITALS 71
    9 BLOOD SCREENING MARKET, BY REGION 72
  • 9.1 INTRODUCTION 73
  • 9.2 NORTH AMERICA 75
    • 9.2.1 U.S. 78
    • 9.2.2 CANADA 81
  • 9.3 EUROPE 83
    • 9.3.1 GERMANY 85
    • 9.3.2 FRANCE 87
    • 9.3.3 U.K. 88
    • 9.3.4 ITALY 90
    • 9.3.5 SPAIN 91
    • 9.3.6 REST OF EUROPE (ROE) 92
  • 9.4 ASIA 93
    • 9.4.1 JAPAN 96
    • 9.4.2 CHINA 97
    • 9.4.3 INDIA 99
    • 9.4.4 REST OF ASIA (ROA) 100
  • 9.5 REST OF THE WORLD (ROW) 102
    10 COMPETITIVE LANDSCAPE 104
  • 10.1 OVERVIEW 104
  • 10.2 MARKET SHARE ANALYSIS 105
    • 10.2.1 MARKET SHARE ANALYSIS FOR NAT 105
    • 10.2.2 BLOOD SCREENING MARKET SHARE ANALYSIS 106
  • 10.3 COMPETITIVE SITUATIONS AND TRENDS 107
    • 10.3.1 PRODUCT LAUNCHES 108
    • 10.3.2 REGULATORY APPROVALS 109
    • 10.3.3 AGREEMENTS 110
    • 10.3.4 PARTNERSHIPS 110
    • 10.3.5 ACQUISITIONS 111
    • 10.3.6 EXPANSIONS 112
      11 COMPANY PROFILES 113
      (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
  • 11.1 INTRODUCTION 113
  • 11.2 GRIFOLS 114
  • 11.3 F. HOFFMANN-LA ROCHE 117
  • 11.4 ABBOTT LABORATORIES 120
  • 11.5 BIOMÉRIEUX 123
  • 11.6 BIO-RAD LABORATORIES, INC. 125
  • 11.7 SIEMENS HEALTHINEERS (A SUBSIDIARY OF SIEMENS AG) 128
  • 11.8 ORTHO CLINICAL DIAGNOSTICS, INC. 130
  • 11.9 THERMO FISHER SCIENTIFIC, INC. 132
  • 11.10 BECKMAN COULTER (A SUBSIDIARY OF DANAHER CORPORATION) 134
  • 11.11 BECTON, DICKINSON AND COMPANY 137
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
12 APPENDIX 139
  • 12.1 DISCUSSION GUIDE 139
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 145
  • 12.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 147
  • 12.4 AVAILABLE CUSTOMIZATIONS 148
  • 12.5 RELATED REPORTS 149
  • 12.6 AUTHOR DETAILS 150

LIST OF TABLES

TABLE 1 BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2014–2021 (USD MILLION) 39
TABLE 2 GLOBAL BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS), 2015 40
TABLE 3 NORTH AMERICA: BLOOD SCREENING MARKET,
BY VOLUME (NUMBER OF TESTS), 2015 40
TABLE 4 EUROPE: BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS), 2015 40
TABLE 5 ASIA: BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS), 2015 41
TABLE 6 BLOOD SCREENING MARKET SIZE FOR NAT, BY COUNTRY,
2014–2021 (USD MILLION) 42
TABLE 7 BLOOD SCREENING MARKET SIZE FOR NAT, BY TYPE, 2014–2021 (USD MILLION) 42
TABLE 8 TMA MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 43
TABLE 9 REAL-TIME PCR MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 44
TABLE 10 BLOOD SCREENING MARKET SIZE FOR ELISA, BY COUNTRY,
2014–2021 (USD MILLION) 45
TABLE 11 BLOOD SCREENING MARKET SIZE FOR ELISA, BY PLATFORM,
2014–2021 (USD MILLION) 45
TABLE 12 CLIA MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 46
TABLE 13 FIA MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 47
TABLE 14 CI MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 48
TABLE 15 BLOOD SCREENING MARKET SIZE FOR ELISA, BY GENERATION,
2014-2021 (USD MILLION) 48
TABLE 16 FIRST-GENERATION ELISA MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 49
TABLE 17 SECOND-GENERATION ELISA MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 50
TABLE 18 THIRD-GENERATION ELISA MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 51
TABLE 19 FOURTH-GENERATION ELISA MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 52
TABLE 20 BLOOD SCREENING MARKET SIZE FOR RAPID TESTS, BY COUNTRY,
2014–2021 (USD MILLION) 53
TABLE 21 BLOOD SCREENING MARKET SIZE FOR WESTERN BLOT ASSAY,
BY COUNTRY, 2014–2021 (USD MILLION) 54
TABLE 22 BLOOD SCREENING MARKET SIZE FOR NGS, BY COUNTRY,
2014–2021 (USD MILLION) 55
TABLE 23 BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 57
TABLE 24 BLOOD SCREENING REAGENTS AND KITS MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 58
TABLE 25 BLOOD SCREENING REAGENTS AND KITS MARKET SIZE, BY TYPE,
2014–2021 (USD MILLION) 58
TABLE 26 NAT REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 59
TABLE 27 NAT REAGENTS & KITS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 60
TABLE 28 ELISA REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 61
TABLE 29 ELISA REAGENTS & KITS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION) 62
TABLE 30 OTHER REAGENTS & KITS MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 63
TABLE 31 BLOOD SCREENING INSTRUMENTS MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 64
TABLE 32 BLOOD SCREENING INSTRUMENTS MARKET SIZE, BY PURCHASE MODE,
2014–2021 (USD MILLION) 65
TABLE 33 RENTAL PURCHASE MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 65
TABLE 34 OUTRIGHT PURCHASE MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 66
TABLE 35 BLOOD SCREENING SOFTWARE AND SERVICES MARKET SIZE,
BY COUNTRY, 2014–2021 (USD MILLION) 67
TABLE 36 BLOOD SCREENING MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 69
TABLE 37 BLOOD SCREENING MARKET SIZE FOR BLOOD BANKS, BY COUNTRY,
2014–2021 (USD MILLION) 70
TABLE 38 BLOOD SCREENING MARKET SIZE FOR HOSPITALS, BY COUNTRY,
2014–2021 (USD MILLION) 71
TABLE 39 GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION,
2012–2019 (USD MILLION) 74
TABLE 40 NORTH AMERICA: BLOOD SCREENING MARKET SIZE, BY COUNTRY,
2014-2021 (USD MILLION) 77
TABLE 41 NORTH AMERICA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014-2021 (USD MILLION) 77
TABLE 42 NORTH AMERICA: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE, 2014–2021 (USD MILLION) 77
TABLE 43 NORTH AMERICA: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 78
TABLE 44 NUMBER OF ORGAN TRANSPLANTATIONS PERFORMED IN THE U.S., 2014-2015 78
TABLE 45 U.S.: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 79
TABLE 46 U.S.: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 80
TABLE 47 U.S.: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 80
TABLE 48 CANADA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 81
TABLE 49 CANADA: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 81
TABLE 50 CANADA: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 82
TABLE 51 EUROPE: BLOOD SCREENING MARKET SIZE, BY COUNTRY,
2014–2021 (USD MILLION) 84
TABLE 52 EUROPE: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 84
TABLE 53 EUROPE: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 84
TABLE 54 EUROPE: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 85
TABLE 55 GERMANY: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 86
TABLE 56 GERMANY: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 86
TABLE 57 GERMANY: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 86
TABLE 58 FRANCE: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 87
TABLE 59 FRANCE: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 88
TABLE 60 FRANCE: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 88
TABLE 61 U.K.: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 89
TABLE 62 U.K.: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 89
TABLE 63 U.K.: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 89
TABLE 64 ITALY: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 90
TABLE 65 ITALY: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 90
TABLE 66 ITALY: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 91
TABLE 67 SPAIN: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 91
TABLE 68 SPAIN: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 92
TABLE 69 SPAIN: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 92
TABLE 70 ROE: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 92
TABLE 71 ROE: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 93
TABLE 72 ROE: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 93
TABLE 73 ASIA: BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 94
TABLE 74 ASIA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 95
TABLE 75 ASIA: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 95
TABLE 76 ASIA: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 95
TABLE 77 JAPAN: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 96
TABLE 78 JAPAN: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 97
TABLE 79 JAPAN: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 97
TABLE 80 CHINA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 98
TABLE 81 CHINA: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 98
TABLE 82 CHINA: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 98
TABLE 83 INDIA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 99
TABLE 84 INDIA: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 99
TABLE 85 INDIA: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 100
TABLE 86 ROA: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 101
TABLE 87 ROA: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 101
TABLE 88 ROA: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 101
TABLE 89 ROW: BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2014–2021 (USD MILLION) 103
TABLE 90 ROW: BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2014–2021 (USD MILLION) 103
TABLE 91 ROW: BLOOD SCREENING MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 103
TABLE 92 PRODUCT LAUNCHES, 2013-2016 108
TABLE 93 REGULATORY APPROVALS, 2013–2016 109
TABLE 94 AGREEMENTS, 2013–2016 110
TABLE 95 PARTNERSHIPS, 2013–2016 111
TABLE 96 ACQUISITIONS, 2013–2016 111
TABLE 97 EXPANSIONS, 2013–2016 112


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 17
FIGURE 2 BLOOD SCREENING MARKET: BOTTOM-UP APPROACH 20
FIGURE 3 TOP-DOWN APPROACH 21
FIGURE 4 DATA TRIANGULATION METHODOLOGY 22
FIGURE 5 BLOOD SCREENING MARKET SIZE, BY PRODUCT AND SERVICE,
2016 VS. 2021 (USD BILLION) 26
FIGURE 6 BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY,
2016 VS. 2021 (USD BILLION) 26
FIGURE 7 BLOOD SCREENING MARKET SIZE, BY END USER, 2016 VS. 2021 (USD BILLION) 27
FIGURE 8 NORTH AMERICA ACCOUNTED FOR THE HIGHEST SHARE OF THE BLOOD SCREENING MARKET IN 2016 28
FIGURE 9 BLOOD SCREENING MARKET TO SHOWCASE LUCRATIVE GROWTH OPPORTUNITIES IN THE FORECAST PERIOD 29
FIGURE 10 NAT SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016 30
FIGURE 11 ASIA TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 30
FIGURE 12 GLOBAL INCIDENCES OF CANCER 34
FIGURE 13 NAT TESTING WILL CONTINUE TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 39
FIGURE 14 REAGENTS & KITS SEGMENT TO HOLD LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD 57
FIGURE 15 BLOOD BANKS SEGMENT WILL CONTINUE TO DOMINATE THE BLOOD SCREENING MARKET DURING THE FORECAST PERIOD 69
FIGURE 16 EMERGING MARKETS OFFER SIGNIFICANT GROWTH OPPORTUNITIES 73
FIGURE 17 ASIAN BLOOD SCREENING MARKET EXPECTED TO GROW AT THE HIGHEST
CAGR DURING THE FORECAST PERIOD 74
FIGURE 18 NORTH AMERICA: MARKET SNAPSHOT 76
FIGURE 19 REAGENTS AND KITS SEGMENT TO HOLD LARGEST SHARE IN THE U.S. MARKET 80
FIGURE 20 EUROPE: MARKET SNAPSHOT 83
FIGURE 21 GERMANY: BLOOD SCREENING MARKET, BY PRODUCT AND SERVICE 85
FIGURE 22 ASIA: BLOOD SCREENING MARKET SNAPSHOT 94
FIGURE 23 ELISA SEGMENT TO GROW AT THE HIGHEST CAGR IN THE JAPANESE MARKET DURING 2016–2021 96
FIGURE 24 BLOOD BANKS END-USER SEGMENT WILL CONTINUE TO DOMINATE THE INDIAN BLOOD SCREENING MARKET TILL 2021 100
FIGURE 25 ROW: MARKET SNAPSHOT 102
FIGURE 26 PRODUCT LAUNCHES, THE KEY STRATEGY ADOPTED BY LEADING PLAYERS 104
FIGURE 27 NAT BLOOD SCREENING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015 105
FIGURE 28 BLOOD SCREENING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015 106
FIGURE 29 BATTLE FOR MARKET SHARE: PRODUCT LAUNCHES, PARTNERSHIPS AND AGREEMENTS, THE KEY GROWTH STRATEGIES ADOPTED BETWEEN 2014 & 2016 107
FIGURE 30 PRODUCT BENCHMARKING OF THE TOP 5 PLAYERS 113
FIGURE 31 GRIFOLS: COMPANY SNAPSHOT 114
FIGURE 32 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT 117
FIGURE 33 ABBOTT LABORATORIES: COMPANY SNAPSHOT 120
FIGURE 34 BIOMÉRIEUX: COMPANY SNAPSHOT 123
FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 125
FIGURE 36 SIEMENS AG: COMPANY SNAPSHOT 128
FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT 132
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT 134
FIGURE 39 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 137

Get in touch!

Looking for sample pages? Or want to speak to someone about discounts?

Please leave your details and we'll get back to you as soon as we can!